2018 Update of the EULAR recommendations for the management of large vessel vasculitis

Bernhard Hellmich, Ana Agueda, Sara Monti, Frank Buttgereit, Hubert De Boysson, Elisabeth Brouwer, Rebecca Cassie, Maria Cinta Cid, Bhaskar Dasgupta, Christian Dejaco, Gulen Hatemi, Nicole Hollinger, Alfred Mahr, Susan P. Mollan, Chetan Mukhtyar, Cristina Ponte, Carlo Salvarani, Rajappa Sivakumar, Xinping Tian, Gunnar Tomasson & 6 others Carl Turesson, Wofgang Schmidt, Peter M. Villiger, Richard Watts, Chris Young, Raashid Ahmed Luqmani

Research output: Contribution to journalArticle

Abstract

Background: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Vasculitis
Rheumatic Diseases
Glucocorticoids
Takayasu Arteritis
Giant Cell Arteritis
Expert Testimony
Refractory materials
Remission Induction
Histology
Biological Factors
Advisory Committees
Therapeutics
Prednisone
Methotrexate
Anticoagulants
Publications
Cohort Studies
Randomized Controlled Trials
Imaging techniques

Keywords

  • Eular recommendations
  • giant cell arteritis
  • large vessel vasculitis
  • management
  • Takayasu arteritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

2018 Update of the EULAR recommendations for the management of large vessel vasculitis. / Hellmich, Bernhard; Agueda, Ana; Monti, Sara; Buttgereit, Frank; De Boysson, Hubert; Brouwer, Elisabeth; Cassie, Rebecca; Cid, Maria Cinta; Dasgupta, Bhaskar; Dejaco, Christian; Hatemi, Gulen; Hollinger, Nicole; Mahr, Alfred; Mollan, Susan P.; Mukhtyar, Chetan; Ponte, Cristina; Salvarani, Carlo; Sivakumar, Rajappa; Tian, Xinping; Tomasson, Gunnar; Turesson, Carl; Schmidt, Wofgang; Villiger, Peter M.; Watts, Richard; Young, Chris; Luqmani, Raashid Ahmed.

In: Annals of the Rheumatic Diseases, 01.01.2019.

Research output: Contribution to journalArticle

Hellmich, B, Agueda, A, Monti, S, Buttgereit, F, De Boysson, H, Brouwer, E, Cassie, R, Cid, MC, Dasgupta, B, Dejaco, C, Hatemi, G, Hollinger, N, Mahr, A, Mollan, SP, Mukhtyar, C, Ponte, C, Salvarani, C, Sivakumar, R, Tian, X, Tomasson, G, Turesson, C, Schmidt, W, Villiger, PM, Watts, R, Young, C & Luqmani, RA 2019, '2018 Update of the EULAR recommendations for the management of large vessel vasculitis', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2019-215672
Hellmich, Bernhard ; Agueda, Ana ; Monti, Sara ; Buttgereit, Frank ; De Boysson, Hubert ; Brouwer, Elisabeth ; Cassie, Rebecca ; Cid, Maria Cinta ; Dasgupta, Bhaskar ; Dejaco, Christian ; Hatemi, Gulen ; Hollinger, Nicole ; Mahr, Alfred ; Mollan, Susan P. ; Mukhtyar, Chetan ; Ponte, Cristina ; Salvarani, Carlo ; Sivakumar, Rajappa ; Tian, Xinping ; Tomasson, Gunnar ; Turesson, Carl ; Schmidt, Wofgang ; Villiger, Peter M. ; Watts, Richard ; Young, Chris ; Luqmani, Raashid Ahmed. / 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. In: Annals of the Rheumatic Diseases. 2019.
@article{84e5362e2df340bfb269d0a477baa7c6,
title = "2018 Update of the EULAR recommendations for the management of large vessel vasculitis",
abstract = "Background: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.",
keywords = "Eular recommendations, giant cell arteritis, large vessel vasculitis, management, Takayasu arteritis",
author = "Bernhard Hellmich and Ana Agueda and Sara Monti and Frank Buttgereit and {De Boysson}, Hubert and Elisabeth Brouwer and Rebecca Cassie and Cid, {Maria Cinta} and Bhaskar Dasgupta and Christian Dejaco and Gulen Hatemi and Nicole Hollinger and Alfred Mahr and Mollan, {Susan P.} and Chetan Mukhtyar and Cristina Ponte and Carlo Salvarani and Rajappa Sivakumar and Xinping Tian and Gunnar Tomasson and Carl Turesson and Wofgang Schmidt and Villiger, {Peter M.} and Richard Watts and Chris Young and Luqmani, {Raashid Ahmed}",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/annrheumdis-2019-215672",
language = "English",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - 2018 Update of the EULAR recommendations for the management of large vessel vasculitis

AU - Hellmich, Bernhard

AU - Agueda, Ana

AU - Monti, Sara

AU - Buttgereit, Frank

AU - De Boysson, Hubert

AU - Brouwer, Elisabeth

AU - Cassie, Rebecca

AU - Cid, Maria Cinta

AU - Dasgupta, Bhaskar

AU - Dejaco, Christian

AU - Hatemi, Gulen

AU - Hollinger, Nicole

AU - Mahr, Alfred

AU - Mollan, Susan P.

AU - Mukhtyar, Chetan

AU - Ponte, Cristina

AU - Salvarani, Carlo

AU - Sivakumar, Rajappa

AU - Tian, Xinping

AU - Tomasson, Gunnar

AU - Turesson, Carl

AU - Schmidt, Wofgang

AU - Villiger, Peter M.

AU - Watts, Richard

AU - Young, Chris

AU - Luqmani, Raashid Ahmed

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

AB - Background: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

KW - Eular recommendations

KW - giant cell arteritis

KW - large vessel vasculitis

KW - management

KW - Takayasu arteritis

UR - http://www.scopus.com/inward/record.url?scp=85068603476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068603476&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2019-215672

DO - 10.1136/annrheumdis-2019-215672

M3 - Article

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -